The primary objective ofthe Biostatistics Core is to contribute to the science and operation ofthe program project by participating fully in its activities as it has forthe preparation of this application. This includes assistance and direction in experimental design, quality control, data collection and management, and statistical data analysis through consultation and collaboration. The team that helps prepare the application and will provide biostatistical supports for this program project consists of the following statisticians from the University of Minnesota and the Masonic Cancer Center: Chap Le (Core Director), Xianghua Luo, Todd DeFor, Yan Zhang, and Flora Fan, an expert in Computational Biology. Together the team from the University of Minnesota is responsible for Project 1, SA2, Project 2, SA1-3, and Project 3, SA2. This team is strengthened with the addition ofthe team from the Medical College of Wisconsin and CIBMTR led by John Klein, PhD (co-Director) and Tao Wang, a statistical geneticist. They wHI be assisted by Alexis Dye, MS a statistical programmer. The team from the Medical College of Wisconsin is responsible for Project 1, SA1 and Project 3, SA1. The assignment of biostatistician support is logical and based on whether the data is collected and stored at the University of Minnesota or transplant data through the National Marrow Donor Program and the CIBMTR at the Medical College of Wisconsin.

Public Health Relevance

The Program Project grant includes a number of clinical trials and research studies that require biostatical support for definitive analysis. This Core contains Faculty and staff at the University of Minnesota for prospective clinical trials and basic research study support. Faculty and staff from the CIBMTR are also included because they curate and are responsible for the unrelated transplant donor data.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA111412-10
Application #
8721717
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
10
Fiscal Year
2014
Total Cost
$148,158
Indirect Cost
$51,669
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
de Witte, Moniek A; Sarhan, Dhifaf; Davis, Zachary et al. (2018) Early Reconstitution of NK and ?? T Cells and Its Implication for the Design of Post-Transplant Immunotherapy. Biol Blood Marrow Transplant 24:1152-1162
Pugh, Jason L; Nemat-Gorgani, Neda; Norman, Paul J et al. (2018) Human NK Cells Downregulate Zap70 and Syk in Response to Prolonged Activation or DNA Damage. J Immunol 200:1146-1158
Cichocki, Frank; Wu, Cheng-Ying; Zhang, Bin et al. (2018) ARID5B regulates metabolic programming in human adaptive NK cells. J Exp Med 215:2379-2395
Grzywacz, Bartosz; Moench, Laura; McKenna Jr, David et al. (2018) Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control. J Immunother :
Sarhan, Dhifaf; Hippen, Keli L; Lemire, Amanda et al. (2018) Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. Cancer Immunol Res 6:766-775
Williams, Robin L; Cooley, Sarah; Bachanova, Veronika et al. (2018) Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. Biol Blood Marrow Transplant 24:618-622
Don Yun, Hyun; Felices, Martin; Vallera, Daniel A et al. (2018) Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells. Blood Adv 2:1580-1584
Cooley, Sarah; Parham, Peter; Miller, Jeffrey S (2018) Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. Blood 131:1053-1062
Williams, Shelly M; Sumstad, Darin; Kadidlo, Diane et al. (2018) Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution. Transfusion 58:1458-1467
Romee, Rizwan; Cooley, Sarah; Berrien-Elliott, Melissa M et al. (2018) First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 131:2515-2527

Showing the most recent 10 out of 108 publications